| Literature DB >> 28642621 |
Wei Zhou1,2, Yi Zhuang1,3, Jiapeng Sun1,2, Xiaofen Wang1,2, Qingya Zhao1,2, Lizhi Xu1,2, Yaping Wang4,5.
Abstract
ATP-binding cassette A3 (ABCA3) is a phospholipid carrier that is mainly expressed in the alveolar epithelium. Biallelic mutations of ABCA3 has been associated with fatal respiratory distress syndrome and interstitial lung disease (ILD) in children. However, whether variations in ABCA3 have a role in the development of adult ILD, including idiopathic pulmonary fibrosis (IPF), remains to be addressed. In this study, we screened for germline variants of ABCA3 by exons-sequencing in 30 patients with sporadic IPF and in 30 matched healthy controls. Eleven missense variants, predominantly in heterozygous, were found in 13 of these patients, but only two missenses in 2 healthy controls. We then selected four of the detected missense variants (p.L39V, p.S828F, p.V968M and p.G1205R) to performed cohort analysis in 1,024 ILD patients, containing 250 IPF and 774 connective tissue disease-ILD (CTD-ILD) patients, and 1,054 healthy individuals. Our results showed that the allele frequency of p.G1205R, but not p.L39V, was significantly higher in ILD patients than in healthy controls. However, no additional subject carrying the variant p.S828F or p.V968M was detected in the cohort analysis. These results indicate that the heterozygous ABCA3 gene variants may contribute to susceptibility to diseases in the Chinese population.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28642621 PMCID: PMC5481373 DOI: 10.1038/s41598-017-04486-y
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Characteristics of the investigated subjects.
| Characteristics# | Number | Male | Female | Mean Age | |
|---|---|---|---|---|---|
| Section 1* | Healthy controls | 30 | 15 | 15 | 66.7 ± 4.3 |
| IPF | 30 | 15 | 15 | 66.7 ± 4.3 | |
| Section 2* | Healthy controls | 1054 | 649 | 405 | 55.6 ± 15.0 |
| ILD | 1024 | 543 | 481 | 60.1 ± 13.5 | |
| CTD-ILD | 774 | 316 | 458 | 58.8 ± 12.9 | |
| IPF | 250 | 227 | 23 | 66.9 ± 10.4 | |
| Pneumonias | 109 | 69 | 40 | 62.9 ± 18.1 |
*The subjects of section 1 were recruited for investigation of the ABCA3 gene by exons-sequencing; The subjects of section 2 were recruited for cohort analysis; #ILD: Interstitial lung diseases; IPF: Idiopathic pulmonary fibrosis; CTD: connective tissue diseases.
The variants detected in ABCA3 gene by sequencing in 30 sporadic IPF patients and 30 healthy controls.
| Types | *No. of subject | Gender | Age | Smoking | Exon | Nucleotide alteration | Amino acid change | &Detection rate | §P value |
|---|---|---|---|---|---|---|---|---|---|
| Missense variants | P-1 | M | 69 | Yes | 15 | c.1809G > C | p.Q603H | 13/30 | 0.002 |
| P-2 | F | 65 | No | 33 | c.5020 G > A | p.G1674S | |||
| P-3 | F | 70 | No | 5 | c.277 G > A | p.V93I | |||
| P-7 | M | 63 | Yes | 24 | c.3613 G > A | p.G1205R | |||
| P-9 | M | 70 | Yes | 19 | c.2483 C > T | p.S828F | |||
| P-10 | F | 62 | No | 5 | c.115 C > G | p.L39V | |||
| P-12 | M | 69 | No | 15 | c.1809G > C | p.Q603H | |||
| P-14 | M | 69 | Yes | 22 | c.3060 T > A | p.N1020K | |||
| P-16 | M | 60 | No | 5 | c.115 C > G | p.L39V | |||
| P-19 | F | 68 | No | 18 | c.2377 G > A | p.E793K | |||
| P-21 | F | 74 | No | 24 | c.3613 G > A | p.G1205R | |||
| P-22 | M | 64 | No | 8 | c.869 T > A, c.2902 G > A | p.L290Q | |||
| 21 | p.V968M | ||||||||
| P-26 | F | 60 | No | 33 | c.4993 A > G | p.I1665V | |||
| H-12 | F | 65 | No | 16 | c.1913G > A | p.R638H | 2/30 | ||
| H-14 | F | 68 | No | 16 | c.2032 G > A | p.A678T | |||
| Synonymous variants | P-1 | M | 69 | Yes | 15 | c.1755C > G | p.P585P | 4/30 | 1.000 |
| P-4 | M | 63 | Yes | 5 | c.213 C > T | p.F71F | |||
| P-12 | M | 69 | No | 5 | c.213 C > T | p.F71F | |||
| P-18 | F | 60 | No | 15 | c.1755C > G | p.P585P | |||
| H-7 | M | 64 | Yes | 15 | c.1755C > G | p.P585P | 3/30 | ||
| H-24 | M | 69 | Yes | 15 | c.1755C > G | p.P585P | |||
| H-29 | F | 73 | No | 5 | c.213 C > T | p.F71F |
*P: Patient number; H: Healthy control number; &Number of carriers detected in 30 IPF patients or 30 healthy controls; §A comparison between the rates of variant carriers in 30 IPF patients and 30 healthy controls (Fisher’s exact test).
The predicted effect of the variants on protein function with bioinformatics assay.
| Variations | dbSNP ID | MAF | SIFT | PolyPhen2 | Pon-P2 | |
|---|---|---|---|---|---|---|
| 1000 G* | ExAC& | |||||
| p.L39V | rs200090198 | 0.0002 | 0.003 | Deleterious | Possibly damaging | Unknown |
| p.F71F | rs117515055 | 0.0056 | 0.0317 | NA† | NA | NA |
| p.V93I | rs199840288 | 0.0004 | 0.003 | Tolerated | Benign | Neutral |
| p.L290Q | NA | Deleterious | Probably damaging | Unknown | ||
| p.P585P | rs323043 | 0.0817 | 0.2018 | NA | NA | NA |
| p.Q603H | rs753223759 | Tolerated | Benign | Neutral | ||
| p.R638H# | rs145269995 | 0.0008 | 0.002 | Tolerated | Benign | Neutral |
| p.A678T# | rs769584477 | Deleterious | Possibly damaging | Unknown | ||
| p.E793K | rs760598605 | Deleterious | Possibly damaging | Unknown | ||
| p.S828F | NA | Deleterious | Probably damaging | Unknown | ||
| p.V968M | rs150340257 | 0.0004 | 0 | Deleterious | Probably damaging | Unknown |
| p.N1020K | NA | Deleterious | Benign | Unknown | ||
| p.G1205R | rs549977217 | 0.0002 | 0.007 | Tolerated | Benign | Unknown |
| p.I1665V | rs781259566 | Tolerated | Benign | Neutral | ||
| p.G1674S | rs202078936 | 0.0006 | 0.003 | Tolerated | Benign | Neutral |
*Minor allele frequency (MAF) from 1000 Genomes Project (1000 G); &MAF from Exome Aggregation Consortium (ExAC) in East Asians; †NA: not available; #The two variants were detected in the healthy controls.
Figure 1Structural diagram of the ABCA3 protein and the distribution of the missense variants detected in ABCA3 in this study. *The two variants were detected in the healthy controls.
Alterations of the putative ESE motifs with these variants detected in sporadic IPF patients and healthy controls.
| Exon | Nucleotide change | ESE-finder* | |||
|---|---|---|---|---|---|
| SF2/ASF | SC35 | SRp40 | SRp55 | ||
| 5 | c.115 C > G | −2/2 | |||
| 5 | c.213 C > T | ||||
| 5 | c.277 G > A | + 1/0 | |||
| 8 | c.869 T > A | +2/0 | −1/1 | ||
| 15 | c.1755C > G | ||||
| 15 | c.1809G > C | −1/1 | +1/0 | +1/0 | +1/0 |
| 16 | c.1913G > A# | ||||
| 16 | c.2032 G > A# | ||||
| 18 | c.2377 G > A | −2/2 | |||
| 19 | c.2483 C > T | −1/1 | |||
| 21 | c.2902 G > A | −1/1 | |||
| 22 | c.3060 A > T | −1/1 | |||
| 24 | c.3613 G > A | +1/0 | |||
| 33 | c.4993 A > G | −1/1 | |||
| 33 | c.5020 G > A | +1/0 | |||
*Number of ESE motifs added or abrogated from the variant/number of ESE motifs in the normal allele; #The two variants were only detected in the healthy controls.
Figure 2Confirmation sequencing of the variants detected in the ABCA3 gene, by using a TaqMan probe. (A,B,C,D) the variants c.115 C > G (p.L39V), c.2483 C > T (p.S828F), c.2902 G > A (p.V968M) and c.3613 G > A (p.G1205R) are shown. (E) the two base pairs substitution, c.3601-3602TT > AA, in the exon 24 in ABCA3. (F) Cloning sequencing confirmed that the substitution of two base pairs occurred in the same copy of the ABCA3 gene, that results in p.F1201N.
Comparisons of allele frequencies on the variants p.L39V and p.G1205R in ABCA3 between ILD patients and healthy controls#.
| Variations | Groups | No. of allele | P-value | OR†(95% CI§) | |
|---|---|---|---|---|---|
| Wild-type allele | Variant allele | ||||
| p.L39V | Control | 2105 | 3 | ||
| ILD | 2044 | 4 | 0.446 | 2.06(0.38–11.26) | |
| Pneumonias | 218 | 0 | 1.000 | 0.99(0.99–1.00) | |
| p.G1205R | Control | 2106 | 2 | ||
| ILD | 2038 | 10 | 0.021 | 5.17(1.13–23.61) | |
| Pneumonias | 214 | 4 | 0.001 | 19.68(3.58–108.08) | |
†odds ratio; §95% confidence interval; #Bonferroni correction was used to adjust the significance level to 0.025.
Comparisons on the variants p.L39V and p.G1205R in ABCA3 between the different subgroups of ILD patients and healthy controls#.
| Variations | Groups | No. of allele | P-value | OR†(95% CI§) | |
|---|---|---|---|---|---|
| Wild-type allele | Variant allele | ||||
| p.L39V | Control | 2105 | 3 | ||
| CTD-ILD | 1546 | 2 | 1.000 | 0.91(0.15–5.45) | |
| IPF | 498 | 2 | 0.246 | 2.83(0.47–17.00) | |
| p.G1205R | Control | 2106 | 2 | ||
| CTD-ILD | 1540 | 8 | 0.022 | 5.49(1.16–25.94) | |
| IPF | 498 | 2 | 0.168 | 4.24(0.60–30.26) | |
†odds ratio; §95% confidence interval; #Bonferroni correction was used to adjust the significance level to 0.025.